| HOME | | | ABOUT ENLYTON | | | OUR TECHNOLOGY | | | PARTNERING OPPORTUNITIES | | | PRESS ROOM | | | CONTACT US |
| ||||||||||||||||||||||||||
| "Enlyton is improving cancer patient care through superior imaging, detection and therapy" | ||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||
About Enlyton
Company Profile
Current methods of imaging are limited in terms of the information provided to oncologists and surgeons. Enlyton has secured exclusive rights to technology that promises to improve the detection limits of diagnostic imaging, enable real-time intraoperative detection of tumor and occult neoplastic tissue, and provide a tumor cell-specific vehicle for localized drug delivery. The company will integrate the first of a series of proprietary molecular targets (“ATA-1”) into cancer-specific imaging agents and detection tools for use in tumor localization and visualization as the means to improve the treatment and management of cancer.
A Collaborative R&D Partnership
Faculty members from The Ohio State University (OSU) Colleges of Medicine, Pharmacy and Engineering are among Enlyton’s founders. An associated understanding with OSU’s Office of Technology Transfer has enabled Enlyton to forge a unique relationship with OSU, the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, where portions of Enlyton’s pre-clinical laboratory experimentation and early stage clinical trial activity will be performed.
Business Strategy
Enlyton draws from resource skills of its clinicians and scientists in the discovery and development of novel imaging and detection tools for diagnostic and prognostic applications in the treatment of cancer. We will pursue partnering and licensing opportunities at various pre-clinical and clinical testing stages for commercialization.